Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis
- 1Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
- 2The First Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China
Abstract
PurposeThis systematic review and meta-analysis aimed to compare the efficacy and safety of antibody-drug conjugates (ADCs) vs. conventional chemotherapy in patients with triple-negative breast cancer (TNBC) and to provide evidence for clinical decision-making and guideline development.MethodsWe systematically searched PubMed, Embase, and Cochrane Library and extracted data including hazard ratio (HR) and 95% confidence interval (CI) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for safety, and objective response rate (ORR).ResultsThis study ultimately included 6 articles (5 dedicated RCTs for TNBC and 1 exploratory analysis of an HR-negative/HER2-low subgroup from the DESTINY-Breast04 trial), including 2,479 patients (1,256 patients in ADCs treatment and 1,223 patients in conventional chemotherapy). HR for PFS was 0.48 [95% CI (0.38, 0.61), P = 0.001], and HR for OS was 0.60 [95% CI (0.46, 0.79), P = 0.027]. OR for incidence of all adverse events (AEs) was 1.05 [95% CI (0.86,1.29), P = 0.901], and OR for incidence of grade ≥ 3 AEs was 1.11 [95% CI (0.88, 1.42), P = 0.984]. The pooled results demonstrated that ADCs significantly improved OS and PFS, while showing no significant increase in overall AEs or grade ≥ 3 AEs compared to control.ConclusionThis study suggests that ADCs significantly improve OS and PFS without significantly increasing grade ≥ 3 AEs compared to conventional chemotherapy in TNBC, providing support for clinical decision-making and guideline development. These findings may inform future head-to-head trials, optimization of ADC-based combination regimens, and biomarker-guided precision treatment. As clinical data on novel ADCs continue to accumulate, these conclusions may be further validated and extended.
Related
- Efficacy and safety of antibody-drug conjugates in advanced small cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials
- Epitope selection for combination therapy using antibody-drug conjugates and immune immune-stimulating antibody conjugates
- Efficacy and Safety of Datopotamab Deruxtecan From a Single-Institution Experience in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer After Multiple Prior Therapies Including Antibody-Drug Conjugates.
- Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates.
- Intracranial Activity of Deruxtecan-Based Antibody–Drug Conjugates in Non-Small Cell Lung Cancer Brain Metastases: A Systematic Review and Meta-Analysis of Prospective Trial Cohorts
BibTeX
@article{wan2026antibodydrug,
title = {{Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis}},
author = {Ke Wan and Ke Wan and Mengxin Liu and Mengxin Liu},
journal = {Frontiers in Medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1975216},
url = {https://doi.org/10.3389/fmed.2026.1975216},
note = {CC BY},
}
RIS
TY - JOUR
TI - Antibody-drug conjugates therapy for triple-negative breast cancer: a systematic review and meta-analysis
AU - Ke Wan
AU - Ke Wan
AU - Mengxin Liu
AU - Mengxin Liu
PY - 2026
DA - 2026/10/26
JO - Frontiers in Medicine
DO - 10.3389/fmed.2026.1975216
UR - https://doi.org/10.3389/fmed.2026.1975216
AB - PurposeThis systematic review and meta-analysis aimed to compare the efficacy and safety of antibody-drug conjugates (ADCs) vs. conventional chemotherapy in patients with triple-negative breast cancer (TNBC) and to provide evidence for clinical decision-making and guideline development.MethodsWe systematically searched PubMed, Embase, and Cochrane Library and extracted data including hazard ratio (HR) and 95% confidence interval (CI) for progression-free survival (PFS) and overall survival (OS), odds ratio (OR) for safety, and objective response rate (ORR).ResultsThis study ultimately included 6 articles (5 dedicated RCTs for TNBC and 1 exploratory analysis of an HR-negative/HER2-low subgroup from the DESTINY-Breast04 trial), including 2,479 patients (1,256 patients in ADCs treatment and 1,223 patients in conventional chemotherapy). HR for PFS was 0.48 [95% CI (0.38, 0.61), P = 0.001], and HR for OS was 0.60 [95% CI (0.46, 0.79), P = 0.027]. OR for incidence of all adverse events (AEs) was 1.05 [95% CI (0.86,1.29), P = 0.901], and OR for incidence of grade ≥ 3 AEs was 1.11 [95% CI (0.88, 1.42), P = 0.984]. The pooled results demonstrated that ADCs significantly improved OS and PFS, while showing no significant increase in overall AEs or grade ≥ 3 AEs compared to control.ConclusionThis study suggests that ADCs significantly improve OS and PFS without significantly increasing grade ≥ 3 AEs compared to conventional chemotherapy in TNBC, providing support for clinical decision-making and guideline development. These findings may inform future head-to-head trials, optimization of ADC-based combination regimens, and biomarker-guided precision treatment. As clinical data on novel ADCs continue to accumulate, these conclusions may be further validated and extended.
SN - 2296-858X
ER -